[ad_1]
STOCKHOLM, February 22, 2019. Modus Therapeutics, the holding company of Karolinska Development, announces today that the first cohort has been
Phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sepsin administration in healthy adults.
Modus Therapeutic is developing sevuparin for diseases with unmet medical needs, with a focus on sickle cell disease, a painful hereditary blood disease that affects millions of people around the world. Sevuparin has the potential to improve the blood flow of MSC patients by reducing their pain and the time they will have to spend in the hospital.
Intravenous sevuparin is currently being tested in a Phase 2 study that was finalized in January 2019 and will report data in mid-2019. To expand the potential of sevuparins to badist SCD patients outside the hospital setting, Modus Therapeutics is exploring in parallel the explanation of sevuparin administered subcutaneously. The first cohort of a single phase-1, single-dose study exploring the pharmacokinetics, safety, and tolerability of subcutaneous sevuparin injections in healthy volunteers was successfully administered in a treatment center. clinical trials in the United States. Sevuparin administered subcutaneously is likely to become a self-administered therapeutic option at home for patients with MSC in the pre- and post-VOC stages – the very painful seizure that would contribute to the progressive accumulation of complications such as that the organ failure and stroke.
In November 2018, the FDA accepted the Modus Therapeutics IND application. The phase 1 sevuparin study administered subcutaneously is the first step in the transfer of clinical development of sevuparin to the United States.
"This is a milestone for Modus Therapeutics as it paves the way for a new treatment option for sickle cell patients and is the beginning of the clinical development of sevuparin in the United States." says Viktor Drvota, CEO of Karolinska Development.
For more information, please contact:
Viktor Drvota, Managing Director, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: [email protected]
To the editors
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic investment company in the life sciences. The company focuses on identifying groundbreaking medical innovations developed by entrepreneurs and management teams in the Nordic region. The company invests in the creation and growth of companies that turn these badets into commercial products designed to improve the lives of patients while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-clbad medical innovations at the Karolinska Institutet and at other leading universities and research institutes in the Nordic region. The company's goal is to create companies composed of leading scientists in their field, backed by experienced management teams and consultants and co-financed by specialized international investors, to provide the best chance of success.
Karolinska Development has built a portfolio of ten companies targeting innovative treatment opportunities for serious or life-threatening debilitating diseases.
The company is led by an entrepreneurial team of investment professionals who have proven themselves as builders of companies and who have access to a strong global network.
For more information, please visit www.karolinskadevelopment.com
-
KD Press Release Modus Feb 2019.pdf
Source link
